Insulin like growth factor‐1 and insulin like growth factor binding proteins in the cerebrospinal fluid and serum from patients with Alzheimer's disease
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Insulin like growth factor‐1 (IGF‐1) is ubiquitously expressed growth factor that has profound effects on the growth and differentiation of many cell types and tissues, including cells of the central nervous system (CNS). IGF‐1 is produced by a wide variety of cells and is found in many biological fluids including cerebrospinal fluid (CSF). IGF‐1 plays important role during CNS development and repair. IGF‐1 has broad range neuroprotective effects and is a therapeutic candidate for Huntington's disease (HD). IGF‐1 protects striatal neurons from the toxicity of mutated Huntington in vitro and improves neuronal survival in vivo in a phenotypic model of HD. Alzheimer's disease (AD) is an age‐dependent dementia characterized by progressive loss of cognitive functions and by characteristic pathological changes in the brain: the formation of aggregates extracellularly by ß‐amyloid (AB) peptide and intracellularly by tau proteins. Since cerebrospinal fluid (CSF) is in contact with the extracellular space of the brain, biochemical brain modifications could be reflected in the CSF. IGFs in circulation and other physiological fluids are associated with a group of high‐affinity binding proteins insulin like growth factor binding proteins (IGFBPs) that specifically bind and modulate their bioactivity at the cellular level. The aim of this study was to determine the level of CSF and serum IGF‐1 and IGFBPs concentrations in the patients with AD. CSF was obtained by lumbar puncture. The presence of IGF‐1 and IGFBPs in the CSF and serum samples was confirmed by Western blot using anti‐IGF‐1 and IGFBPs antibodies. Using enzyme linked immunosorbent assay (ELISA), it was shown that the concentration of CSF and serum IGF‐1 and IGFBPs in the patients with AD is higher than in normal control. The data from this study indicate that IGF‐1 is a constant component of human CSF. It is also concluded that high levels of CSF IGF‐1 may be partly related to AD pathophysiology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Murer, M. G., Yan, Q., & Raisman-Vozari, R. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00014-9 · Cited by 874
Insulin-Like Growth Factor-I and Central Nervous System Development
Anlar, B., Sullivan, K., & Feldman, E. (1999) · Hormone and Metabolic Research · doi:10.1055/s-2007-978708 · Cited by 175
Cited by
Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
M. de la Monte, S. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015037 · Cited by 448
Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease
Doecke, J. D. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1282 · Cited by 421
Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?
Bassil, F., Fernagut, P.-O., Bezard, E., & Meissner, W. G. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.02.005 · Cited by 309
Aberrant insulin signaling in Alzheimer's disease: current knowledge
Bedse, G., Di Domenico, F., Serviddio, G., & Cassano, T. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00204 · Cited by 292
de la Monte, S. M. (2012) · Drugs · doi:10.2165/11597760-000000000-00000 · Cited by 265
“deficiency,([134,135]) highlighting the fact that function of the entire insulin/IGF family of genes is dysregulated in AD.”
Background
Metadata
- Authors
- Salehi, Z., Mashayekhi, F., & Naji, M.
- Venue
- BioFactors
- Publisher
- Wiley
- Published
- 2008-01
- Volume
- 33
- Issue
- 2
- Pages
- 99-106
- ISSN
- 0951-6433 (ISSN-L)
- 1872-8081
- OpenAlex
- W2137622685
- Cited by
- 71
- References
- 2
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.